Gallium-68-P16 093

Drug Profile

Gallium-68-P16 093

Alternative Names: [68Ga]P16-093

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Five Eleven Pharma
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Emission-computed tomography enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer; Renal cancer

Most Recent Events

  • 21 Jul 2017 Phase-I clinical trials in Prostate cancer (Diagnosis, Metastatic disease) in USA (IV) (NCT03073395)
  • 21 Jul 2017 Phase-I clinical trials in Renal cancer (Diagnosis, Metastatic disease) in USA (IV) (NCT03073395)
  • 10 Mar 2017 Five Eleven Pharma plans a phase I trial for Prostate and Renal cancer (Metastatic disease, Diagnosis) in USA (IV, Injection) (NCT03073395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top